Related references
Note: Only part of the references are listed.Structural and Functional Characterization of the Secondary Mutation N126K Selected by Various HIV-1 Fusion Inhibitors
Danwei Yu et al.
VIRUSES-BASEL (2020)
Structural and functional characterization of HIV-1 cell fusion inhibitor T20
Xiujuan Zhang et al.
AIDS (2019)
HIV-1 anchor inhibitors and membrane fusion inhibitors target distinct but overlapping steps in virus entry
Dirk Eggink et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2019)
Exceptional potency and structural basis of a T1249-derived lipopeptide fusion inhibitor against HIV-1, HIV-2, and simian immunodeficiency virus
Yuanmei Zhu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2018)
Mechanism of HIV-1 Resistance to an Electronically Constrained α-Helical Peptide Membrane Fusion Inhibitor
Xiyuan Wu et al.
JOURNAL OF VIROLOGY (2018)
Enfuvirtide (T20)-Based Lipopeptide Is a Potent HIV-1 Cell Fusion Inhibitor: Implications for Viral Entry and Inhibition
Xiaohui Ding et al.
JOURNAL OF VIROLOGY (2017)
A Lipopeptide HIV-1/2 Fusion Inhibitor with Highly Potent In Vitro, Ex Vivo, and In Vivo Antiviral Activity
Huihui Chong et al.
JOURNAL OF VIROLOGY (2017)
Mechanism of HIV-1 Resistance to Short-Peptide Fusion Inhibitors Targeting the Gp41 Pocket
Yang Su et al.
JOURNAL OF VIROLOGY (2015)
Genetic Pathway of HIV-1 Resistance to Novel Fusion Inhibitors Targeting the Gp41 Pocket
Yang Su et al.
JOURNAL OF VIROLOGY (2015)
Two M-T hook residues greatly improve the antiviral activity and resistance profile of the HIV-1 fusion inhibitor SC29EK
Huihui Chong et al.
RETROVIROLOGY (2014)
Broad Antiviral Activity and Crystal Structure of HIV-1 Fusion Inhibitor Sifuvirtide
Xue Yao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
The M-T Hook Structure Is Critical for Design of HIV-1 Fusion Inhibitors
Huihui Chong et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
In Vitro Selection and Characterization of HIV-1 Variants with Increased Resistance to Sifuvirtide, a Novel HIV-1 Fusion Inhibitor
Zhonghua Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Virus-cell and cell-cell fusion mediated by the HIV-1 envelope glycoprotein is inhibited by short gp41 N-terminal membrane-anchored peptides lacking the critical pocket domain
Yael Wexler-Cohen et al.
FASEB JOURNAL (2010)
Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency
Paolo Ingallinella et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41
L Xu et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV
JJ Eron et al.
JOURNAL OF INFECTIOUS DISEASES (2004)
Enfuvirtide: A fusion inhibitor for the treatment of HIV infection
HB Fung et al.
CLINICAL THERAPEUTICS (2004)
Resistance to enfuvirtide, the first HIV fusion inhibitor
ML Greenberg et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2004)
An inducible HIV type 1 gp41 HR-2 peptide-binding site on HIV type 1 envelope gp120
SM Alam et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2004)
A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy
JP Lalezari et al.
AIDS (2003)
Design of a novel peptide inhibitor of HIV fusion that disrupts the internal trimeric coiled-coil of gp41
CA Bewley et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Protein design of an HIV-1 entry inhibitor
MJ Root et al.
SCIENCE (2001)
Share Paper
